Pyridopyrazinone Derivatives Glucose-Dependent Insulin Secretion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for type 2 diabetes, such as sulfonylureas and GLP-1 analogs, either induce sustained hyperinsulinemia with side effects or require parenteral administration, failing to restore normal glucose-induced insulin secretion and preserve beta cell mass effectively.
Innovation Solution
Development of specific pyridopyrazinone derivatives that stimulate insulin secretion in response to glucose levels, addressing the defects in insulin secretion and beta cell function in type 2 diabetes without causing hyperinsulinemia or requiring parenteral administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If sulfonylureas are used to induce insulin secretion, then insulin release is increased, but sustained hyperinsulinemia and side effects occur
Solution Approach 1:
The pyridopyrazinone derivatives act as glucose-dependent insulin secretagogues, meaning they stimulate insulin secretion only in the presence of elevated glucose levels. This glucose-dependent mechanism provides physiological feedback control, preventing sustained hyperinsulinemia and associated side effects while maintaining effective insulin secretion when needed.
Solution Approach 2:
The invention changes the key parameter of insulin secretion from being drug-driven (sulfonylureas) to being glucose-driven (physiological response). This parameter change transforms the secretion profile from sustained and non-selective to pulsatile and glucose-responsive, eliminating hyperinsulinemia while preserving beneficial insulin release.
2Reliability
If GLP-1 analogs are used to restore normal insulin release profile, then beta cell function is preserved, but parenteral administration is required
Solution Approach 1:
The invention substitutes the peptide-based GLP-1 mechanism with a small molecule compound that achieves similar physiological effects through oral administration. This replaces the parenteral delivery system with an oral tablet, eliminating injection requirements while maintaining glucose-dependent insulin secretion and beta cell protective effects.
Solution Approach 2:
The invention changes the molecular class from peptide (GLP-1 analog) to small molecule (pyridopyrazinone derivative), which fundamentally alters the administration route parameter from parenteral to oral, improving patient compliance and ease of use while preserving the therapeutic effect.
3Productivity
If sulfonylureas are used to stimulate insulin secretion, then blood glucose is lowered, but beta cell exhaustion and secondary failure occur
Solution Approach 1:
The glucose-dependent mechanism of pyridopyrazinone derivatives provides physiological feedback that limits insulin secretion to periods of hyperglycemia. This prevents prolonged and excessive insulin release that causes beta cell exhaustion, thereby preserving beta cell mass and function over the long term while maintaining effective blood glucose control.
Solution Approach 2:
The invention transforms insulin secretion from continuous (sulfonylurea-induced) to periodic and pulsatile (glucose-dependent). This periodic action allows beta cells to rest during euglycemic periods, preventing exhaustion and maintaining long-term secretory capacity while achieving effective glucose control during hyperglycemic episodes.
Data Source
AI summary
The present invention relates to pyridopyrazinone derivatives of formula (I), wherein X, Y, Z1 W, A and R1 are as defined in claim 1, as insulin secretion stimulators. The invention also relates to the preparation and use of these pyridopyrazinone derivatives for the prophylaxis and/or treatment of diabetes and pathologies associated.